|
|
| | Zagotenemab Basic information |
| Product Name: | Zagotenemab | | Synonyms: | Zagotenemab;Research Grade Zagotenemab(DHC82402);Zagotenemab (anti-Tau);LY33003560;Research Grade Zagotenemab | | CAS: | 2019133-28-7 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Zagotenemab Structure]() |
| | Zagotenemab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Zagotenemab Usage And Synthesis |
| Uses | Zagotenemab (LY3303560) is a humanised anti-tau antibody that selectively binds and neutralises tau deposits in the brain. Zagotenemab can be used in Alzheimer's disease research[1]. | | References | [1] Abyadeh M, et al. Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer's Disease. Aging Dis. 2021 Dec 1;12(8):1964-1976. DOI:10.14336/AD.2021.0719 |
| | Zagotenemab Preparation Products And Raw materials |
|